Federal actuaries predict retail prescription drug spending in the United States will grow 4.3% this year, with growth accelerating to 4.7% next year and to 5.1% in 2024.
Category: Pharma Industry
News Alert
HRSA Refers Boehringer Ingelheim to HHS Inspector General over its 340B Contract Pharmacy Policy
The U.S. Health Resources and Services Administration (HRSA) today turned the screws tighter on Boehringer Ingelheim (BI) over its “continued failure to provide the 340B price to covered entities utilizing contract pharmacies.”
Please Login or Become
Arkansas health centers asked a federal court yesterday to let them intervene in the drug industry lawsuit challenging the state’s one-of-a-kind law protecting 340B contract pharmacy arrangements.
Please Login or Become a Paid Subscriber to View
Generic-drug manufacturer BioComp is offering covered entities refunds for lower 340B prices that it did not pay on six NDCs for periods over eight years, starting in Q3 2013 and ending in Q2 2021.
Please Login
HIV/AIDS Advocates Protest in Front of Gilead HQ Against Company’s New 340B Contract Pharmacy Policy
AIDS Healthcare Foundation (AHF), the world’s largest AIDS provider organization, held a demonstration yesterday in front of drug manufacturer Gilead’s San Francisco Bay area headquarters protesting the company’s new conditions on 340B contract pharmacy pricing on its branded hepatitis C
…
Bristol Myers Squibb (BMS) is providing 340B covered entities wholesaler credits for overcharges during Q3 2021 on one new NDC of its flagship cancer drug Opdivo.
Please Login or Become a Paid Subscriber to View this
J&J is the world’s biggest drug company. Its decision to restrict 340B pricing when hospitals use contract pharmacies could be a thunderclap that rouses Congress.
Please Login or Become a Paid Subscriber to View this Content
Drug manufacturer Johnson & Johnson this afternoon announced conditions on 340B sales on 29 products—including several of its top-selling drugs—when hospitals use contract pharmacies.
Please Login or Become a Paid Subscriber to View this Content
The National Association of Community Health Centers (NACHC) told drug manufacturer Gilead this morning its new conditions on 340B contract pharmacy pricing on its branded hepatitis C treatments are “unconscionable,” “appalling,” “wrongheaded,” and “the latest example of corporate greed from
…
HIV/AIDS clinics and hospitals that participate in the 340B program are condemning drug manufacturer Gilead’s new conditions on 340B pricing on its branded hepatitis C treatments when covered entities use contract pharmacies.